BEAM

Beam is a pre-commercial gene-editing platform whose FY2025 'revenue' of $140M (up 120% YoY) is collaboration/licensing income, not product sales — the underlying business is a $410M R&D program funded by capital markets. Operating income of -$384M against $140M of revenue (operating margin -274.6%) and operating cash flow of -$345M tell the real story: cash & equivalents of $295M cover less than one year of operations at the current burn. The 10-K's Risk Factors lead with 'our need to raise additional funding' and explicitly warn that deteriorating equity markets could make financing 'more difficult, more costly, and more dilutive' — and shares outstanding already grew 21.7% in FY2025, confirming the dilution treadmill is active.

The MD&A frames the company honestly as a platform play: a 'long-term, staged development strategy' anchored by risto-cel for sickle cell disease in the Phase 1/2 BEACON trial (~50 patients) plus an in vivo HSC wave that is even earlier. None of this generates product revenue in the near term, and the lumpy revenue history ($378M in FY2023 collapsing to $63.5M in FY2024 then bouncing to $140M in FY2025) confirms the top line is milestone-driven and non-recurring — using it to compute a 24.7x P/S is misleading. Stockholders' equity grew 68.8% to $1.24B not from earnings but because retained earnings deepened to -$1.64B while paid-in capital rose, i.e. they sold stock.